Summit Corporation plc  

(Public, LON:SUMM)   Watch this stock  
Find more results for SUMM
-0.90 (-0.71%)
Jan 30 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 125.40 - 130.00
52 week 100.00 - 239.50
Open 127.00
Vol / Avg. 66,963.00/27,607.00
Mkt cap 51.36M*
P/E     -
Div/yield     -
EPS -0.33*
Shares 41.12M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Jul '14) 2014
Net profit margin -1028.92% -443.13%
Operating margin -1114.46% -487.93%
EBITD margin - -487.05%
Return on average assets -78.45% -110.70%
Return on average equity -95.14% -160.07%
Employees 17 -
CDP Score - -


85b Park Drive,Milton Park
United Kingdom - Map
+44-1235-443939 (Phone)
+44-1235-436237 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Summit Corporation plc (Summit) is a United Kingdom-based drug discovery and development company. The Company is engaged in developing drug candidates to treat Duchenne Muscular Dystrophy (DMD), a fatal genetic disease, and Clostridium difficile Infection (CDI), an infectious disease. The Company is advancing a broad pipeline of utrophin modulators that comprise its lead candidate SMT C1100 and next generation modulators that are at an earlier stage of development. It is in a Phase 1b clinical trial. The Company is developing SMT19969 as a differentiated, novel antibiotic that is a potential treatment for initial CDI that could significantly reduce rates of recurrent disease. SMT19969 completed a Phase 1 clinical trial in healthy volunteers with the results showing it to be safe and well tolerated at all doses tested, including the expected therapeutic dose. The Company�s subsidiaries include Summit (Oxford) Limited and Summit (Wales) Limited.

Officers and directors

Glyn Edwards Chief Executive Officer, Executive Director
Age: 58
Erik Ostrowski Chief Financial Officer
Age: 41
Frank Murdoch Armstrong Non-Executive Chairman of the Board
Age: 56
Valerie L. Andrews Non-Executive Director
Age: 55
Stephen J. Davies Non-Executive Director
Age: 64
Barry J. Price Ph.D. Non-Executive Director
Age: 70
Leopoldo Zambeletti Non-Executive Director
Age: 45